For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
 Johnson & JohnsonJNJ US · Health Care · USD Current price$269.19as of Sep 22, 2026 Summary
Analyst consensusStrong Buy 5Buy 11Hold 6Sell 122 analysts 3-year price (USD)Factor profileMulti-factor score 84 / 100 Market data
Business descriptionJohnson & Johnson (J&J) is a global healthcare giant operating in Pharmaceuticals and MedTech. It is a leader in a wide array of healthcare categories, including immunology, oncology, and vision care. Competitive moatJ&J possesses an unparalleled R&D budget and a highly diversified revenue stream. In Vision Care, it is the global leader in the contact lens market and a primary competitor in the intraocular lens (IOL) space. Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: $269.19 · Sep 22, 2026· USD
CFRA Ratingbuy
TBI Multi Score84
Theme Exposure
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: JNJBusiness description
Johnson & Johnson (J&J) is a global healthcare giant operating in Pharmaceuticals and MedTech. It is a leader in a wide array of healthcare categories, including immunology, oncology, and vision care.
Competitive moat
J&J possesses an unparalleled R&D budget and a highly diversified revenue stream. In Vision Care, it is the global leader in the contact lens market and a primary competitor in the intraocular lens (IOL) space.
Recent developments
- Vision Care Competition: J&J's PureSee IOL is projected to pressure Alcon AG's US PC-IOL franchise in 2026, highlighting J&J's aggressive innovation in the surgical eye care space.
- Portfolio Pivot: Following the spinoff of its consumer health division (Kenvue), J&J is now a more focused, higher-margin healthcare entity.
Investment risks / red flags
- Litigation: Like all major pharma companies, it faces ongoing legal risks related to product liability.
- Drug Pricing: Exposure to regulatory changes and pricing pressure in the US pharmaceutical market.
Market Data
Source: mkts.io · Sep 22, 2026, 22:00 UTC
Key Metrics
P/E (TTM)31.23
P/E (Fwd)22.18
Dividend1.99%
Beta0.23
52W High$281.07
52W Low$174.83
Analyst Consensus
5
11
6
Strong Buy5Buy11Hold6Sell122 analysts
Consensus Target$277.91
+3.2% upside
Calendar Events
Next EarningsOct 13, 2026
Ex-DividendAug 25, 2026
Dividend DateSep 8, 2026
Financials
Revenue$97.93B
Rev Growth6.60%
Earnings Growth-0.90%
Gross Margin68.14%
Op Margin29.19%
Profit Margin21.48%
EBITDA$34.87B
ROA8.60%
ROE25.74%
Rev/Share$40.67
Total Cash$20.76B
Total Debt$49.04B
D/E Ratio57.71
Free Cash Flow$16.89B
Op Cash Flow$27.61B
Current Ratio1.09
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 2.45 | $25.29B |
| +1q | 2.97 | $26.51B |
| 0y | 11.07 | $101.22B |
| +1y | 12.14 | $108.72B |
Earnings
Quarterly EPS
3Q2025
Est: 2.762.80Beat
4Q2025
Est: 2.462.46Miss
1Q2026
Est: 2.682.70Beat
2Q2026
Est: 2.852.90Beat
Annual
2022
Rev $94.94BEarn $17.94B
2023
Rev $85.16BEarn $35.15B
2024
Rev $88.82BEarn $14.07B
2025
Rev $94.19BEarn $26.80B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Sep 10, 2026 | HSBC | main | Buy |
| Sep 2, 2026 | UBS | main | Buy |
| Aug 6, 2026 | Guggenheim | main | Buy |
| Aug 3, 2026 | Wells Fargo | main | Overweight |
| Jul 17, 2026 | Guggenheim | reit | Buy |
| Jul 16, 2026 | Raymond James | main | Outperform |